Enanta sues Pfizer in EU UPC for Paxlovid patent infringement

ENANTA PHARMACEUTICALS INC

Filed suit in Unified Patent Court (action 35071/2025) alleging Pfizer's Paxlovid infringes European Patent EP 4 051 265.
Action covers 18 EU countries participating in UPC; patent based on July 2020 application for coronavirus protease inhibitors.
European counterpart of US Patent 11,358,953, which is already subject to ongoing US litigation between Enanta and Pfizer.
Hearing expected within 12-month UPC target; decision within weeks thereafter, subject to appeal.
No damages determination yet; if infringement found, separate proceedings would assess damages.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.